Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. on January 5, 2018, reporting events occurring on December 29, 2017. The filing discloses the entry into a material definitive agreement involving a new term loan facility.
Key Financial Metrics and Debt Structure
The filing details a new debt instrument rather than operational financial performance metrics such as revenue or profit.
- Principal Amount: $20,000,000
- Lender: Silicon Valley Bank
- Interest Rate: Floating rate equal to 1.25% above the Wall Street Journal Prime Rate
- Maturity Date: December 1, 2021
- Repayment Terms: Monthly interest-only payments through March 29, 2019, followed by 33 equal monthly installments of principal plus interest.
- Final Payment: Includes all outstanding principal and accrued interest, plus an additional 8% of the original aggregate principal amount.
- Upfront Costs: $50,000 non-refundable commitment fee plus reimbursement of certain bank expenses.
- Collateral: Substantially all company assets, excluding intellectual property.
Material Changes and Prepayment Terms
The company entered into a new Loan and Security Agreement, creating a direct financial obligation. The agreement includes specific prepayment fees based on the timing of repayment:
- Within 1 year: 2% of the prepaid principal amount.
- Between 1 and 2 years: 1% of the prepaid principal amount.
- Between 2 and 3 years: 0.5% of the prepaid principal amount.
- After 3 years: 0% prepayment fee.
Guidance, Outlook, and Risks
The company intends to use the loan proceeds for general corporate purposes. On January 5, 2018, Zafgen issued a press release (Exhibit 99.1) discussing the loan alongside clinical progress and a 2018 outlook; however, the specific details of this outlook are not contained within the text of this 8-K filing.
Risks and Covenants: The agreement requires the company to maintain customary financial covenants. Events of default include non-payment, covenant violations, bankruptcy, and material judgments. The filing notes that the press release information is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the current Wall Street Journal Prime Rate to calculate the exact effective interest rate.
- Review the full Loan and Security Agreement (Exhibit 10.1) for specific financial covenants and definitions of "material judgments."
- Examine the press release (Exhibit 99.1) for details on the 2018 clinical outlook and specific use of proceeds.
- Confirm the company's current cash position to assess the ability to service the interest-only payments starting immediately.
- Note that the filing references "Zafgen, Inc." despite the request metadata mentioning "Larimar Therapeutics, Inc." (Larimar was formed later via a merger with Zafgen).